News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Sep 28, 2020

Astellas' Real-World Evidence Studies Provide Further Insight into Negative Impacts of Vasomotor Symptoms (VMS) Associated with Menopause

New findings to be presented at The North American Menopause Society (NAMS) 2020 Virtual Annual Meeting
Sep 23, 2020

Astellas Establishes Global Patient Centricity Leadership Structure to Incorporate Patient Perspectives Across Research and Development Continuum
- Photos 1
Sep 18, 2020

Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

- Trial Stopped Early Due to Positive Results at Planned Interim Analysis -
Sep 15, 2020

Astellas Ranks Among Top Companies for Working Parents
Sep 1, 2020

The Astellas Global Health Foundation Provides $2 Million In COVID-19 Relief To Six Organizations Serving More Than 725,000 Lives In Vulnerable Communities In Seven Countries

Recent grants and redirected funding help to respond to the COVID-19 pandemic by improving healthcare infrastructure, training and education in low-income countries
Aug 4, 2020

Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award the Best Innovations in Cancer Care Beyond Medicine

-Tackling everyday challenges in cancer care, apply by September 28, 2020-
Jul 23, 2020

Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research

Astellas "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas
Jul 22, 2020

Astellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062 to Investigate Potential Novel Therapeutic Approach to Address the Opioid Crisis
Jun 8, 2020

Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease

- Study meets primary endpoint demonstrating non-inferiority of roxadustat to darbepoetin in correction and maintenance of hemoglobin levels
May 29, 2020

Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer

Data simultaneously published in the New England Journal of Medicine and presented during the virtual scientific program of the 2020 ASCO Annual Meeting

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products